A review of vaccine clinical trials for non-small cell lung cancer.
Recent evidence suggests that vaccines which enhance tumour antigen recognition may provide clinical benefit to subsets of non-small cell lung cancer patients. In this review, a variety of peptide-, gene- and cell-based clinical vaccine approaches targeting non-small cell lung cancer patients are reviewed. Results consistently demonstrate lack of toxicity. Examples of prolonged stable disease, tumour shrinkage response and survival benefit in comparison with historical and low-dose control groups have been demonstrated. Specific vaccines fulfilling justification for Phase III evaluation based on these results include LBLP25, TGF-beta2 antisense gene vaccine and GVAX.
Nemunaitis
J
J
Mary Crowley Medical Research Center, 60th Floor, 1717 Main St, Dallas, Texas 75201, USA. jnemunaitis@mcmrc.com
Nemunaitis
J
J
D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control*; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic / Q000401:mortality; D015996:Survival Rate
D019496:Cancer Vaccines